{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/generalized-anxiety-disorder/how-this-topic-was-developed/stakeholder-engagement/","result":{"pageContext":{"chapter":{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement","depth":2,"htmlHeader":"<!-- begin field 19cf2f83-2faa-42e5-99d2-a7f201763884 --><h2>Stakeholder engagement</h2><!-- end field 19cf2f83-2faa-42e5-99d2-a7f201763884 -->","summary":null,"htmlStringContent":"<!-- begin item e8063278-9c7d-44e3-bc63-a7f20174d91e --><!-- begin field 1b487005-835e-41b7-b173-a7f201763884 --><h2>Our policy</h2><!-- end field 1b487005-835e-41b7-b173-a7f201763884 --><!-- begin field 333ace9b-7db8-4ddd-be40-a7f201763884 --><p>The external review process is an essential part of CKS topic development. Consultation with a wide range of stakeholders provides quality assurance of the topic in terms of:</p><ul><li>Clinical accuracy.</li><li>Consistency with other providers of clinical knowledge for primary care.</li><li>Accuracy of implementation of national guidance (in particular NICE guidelines).</li><li>Usability.</li></ul><!-- end field 333ace9b-7db8-4ddd-be40-a7f201763884 --><!-- begin field 3a52e87f-0c3d-4eb4-92a6-a7f201763884 --><h2>Principles of the consultation process</h2><!-- end field 3a52e87f-0c3d-4eb4-92a6-a7f201763884 --><!-- begin field 925a1a69-4ac7-424c-942b-a7f201763884 --><ul><li>The process is inclusive and any individual may participate.</li><li>To participate, an individual must declare whether they have any competing interests or not. If they do not declare whether or not they have competing interests, their comments will not be considered.</li><li>Comments received after the deadline will be considered, but they may not be acted upon before the clinical topic is issued onto the website.</li><li>Comments are accepted in any format that is convenient to the reviewer, although an electronic format is encouraged.</li><li>External reviewers are not paid for commenting on the draft topics.</li><li>Discussion with an individual or an organization about the CKS response to their comments is only undertaken in exceptional circumstances (at the discretion of the Clinical Editor or Editorial Steering Group).</li><li>All reviewers are thanked and offered a letter acknowledging their contribution for the purposes of appraisal/revalidation.</li><li>All reviewers are invited to be acknowledged on the website. All reviewers are given the opportunity to feedback about the external review process, enabling improvements to be made where appropriate.</li></ul><!-- end field 925a1a69-4ac7-424c-942b-a7f201763884 --><!-- begin field bbdfa3d9-f9a2-4514-a15f-a7f201763884 --><h2>Stakeholders</h2><!-- end field bbdfa3d9-f9a2-4514-a15f-a7f201763884 --><!-- begin field 248ea47e-313d-4b5a-81e1-a7f201763884 --><ul><li>Key stakeholders identified by the CKS team are invited to comment on draft CKS topics. Individuals and organizations can also register an interest to feedback on a specific topic, or topics in a particular clinical area, through the <a href=\"http://cks.clarity.co.uk/get-involved/\" data-hyperlink-id=\"1bf5f421-6cfc-49c9-a150-a9910171fbc4\">Getting involved</a> section of the <a href=\"https://clarity.co.uk/\" data-hyperlink-id=\"12756184-8d64-4428-8fdb-a9910171fcac\">Clarity Informatics</a> website.</li><li>Stakeholders identified from the following groups are invited to review draft topics:<ul><li>Experts in the topic area.</li><li>Professional organizations and societies (for example, Royal Colleges).</li><li>Patient organizations, Clarity has established close links with groups such as Age UK and the Alzheimer’s Society specifically for their input into new topic development, review of current topic content and advice on relevant areas of expert knowledge.</li><li>Guideline development groups where the topic is an implementation of a guideline.</li><li>The British National Formulary team.</li><li>The editorial team that develop MeReC Publications.</li></ul></li><li>Reviewers are provided with clear instructions about what to review, what comments are particularly helpful, how to submit comments, and declaring interests.</li></ul><!-- end field 248ea47e-313d-4b5a-81e1-a7f201763884 --><!-- begin field d82c3fe5-dba5-4367-b1f6-a7f201763884 --><h2>Patient engagement</h2><!-- end field d82c3fe5-dba5-4367-b1f6-a7f201763884 --><!-- begin field 324cdc41-08fc-4491-a155-a7f201763884 --><p>Clarity Informatics has enlisted the support and involvement of patients and lay persons at all stages in the process of creating the content which include:</p><ul><li>Topic selection</li><li>Scoping of topic</li><li>Selection of clinical scenarios</li><li>First draft internal review</li><li>Second draft internal review</li><li>External review</li><li>Final draft and pre-publication</li></ul><p>Our lay and patient involvement includes membership on the editorial steering group, contacting expert patient groups, organizations and individuals.</p><!-- end field 324cdc41-08fc-4491-a155-a7f201763884 --><!-- end item e8063278-9c7d-44e3-bc63-a7f20174d91e -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","fullItemName":"Management","slug":"management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"795e451d-3583-5146-ab5d-137780924ebc","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}